Finasteride - Elorac

Drug Profile

Finasteride - Elorac

Latest Information Update: 02 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Elorac
  • Class Androstenes; Antiacnes; Antiandrogens; Antineoplastics; Azasteroids; Small molecules
  • Mechanism of Action Cholestenone 5-alpha reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Acne vulgaris

Most Recent Events

  • 06 Jun 2017 Elorac completes a phase II trial in Acne vulgaris in USA (PO) (NCT02502669)
  • 21 Mar 2017 Finasteride is still in phase II trials for Acne vulgaris in USA (PO)
  • 15 Mar 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top